What is Applied Genetic Technologies Median PS Value?
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Applied Genetic Technologies's Median PS Value or its related term are showing as below:
AGTC's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.7 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Applied Genetic Technologies Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Applied Genetic Technologies Median PS Value Chart
Competitive Comparison of Applied Genetic Technologies's Median PS Value
For the Biotechnology subindustry, Applied Genetic Technologies's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied Genetic Technologies's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Applied Genetic Technologies's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Applied Genetic Technologies's Price-to-Median-PS-Value falls into.
Applied Genetic Technologies Median PS Value Calculation
10-Year Median PS Ratio is 0.
Applied Genetic Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.006.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied Genetic Technologies (NAS:AGTC) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Applied Genetic Technologies's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.3936
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied Genetic Technologies Median PS Value Related Terms
Thank you for viewing the detailed overview of Applied Genetic Technologies's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Applied Genetic Technologies (Applied Genetic Technologies) Business Description
Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGTC has been successfully added to your 